Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $21.29.

A number of research analysts have recently weighed in on RCUS shares. Wedbush reissued an "outperform" rating and issued a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Morgan Stanley cut their price objective on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Barclays dropped their price target on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Wells Fargo & Company decreased their price objective on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group decreased their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th.

Arcus Biosciences Stock Up 1.3%

RCUS traded up $0.12 during trading on Friday, reaching $9.27. 599,750 shares of the stock traded hands, compared to its average volume of 887,741. The stock has a market cap of $981.18 million, a price-to-earnings ratio of -2.21 and a beta of 0.80. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.37 and a quick ratio of 5.37. The stock's 50-day simple moving average is $8.97 and its two-hundred day simple moving average is $9.92.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 70.58% and a negative net margin of 258.94%. The business had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. During the same period in the prior year, the firm posted ($0.05) EPS. Arcus Biosciences's revenue for the quarter was down 80.7% on a year-over-year basis. As a group, equities research analysts expect that Arcus Biosciences will post -3.15 EPS for the current year.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of RCUS. Gilead Sciences Inc. boosted its stake in Arcus Biosciences by 4.5% in the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company's stock worth $246,684,000 after purchasing an additional 1,363,636 shares in the last quarter. Vanguard Group Inc. lifted its stake in Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock worth $52,499,000 after acquiring an additional 1,298,584 shares during the last quarter. Woodline Partners LP raised its stake in Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock valued at $40,249,000 after acquiring an additional 1,603,367 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Arcus Biosciences by 11.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock worth $25,348,000 after acquiring an additional 178,351 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Arcus Biosciences in the 4th quarter valued at about $23,857,000. Institutional investors own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.